Sotoxen 320 mg (Sotorasib INN)

KRAS G12C Inhibitor for Targeted Lung Cancer Therapy

💊 Pharmacology:

Sotorasib is a selective KRAS G12C inhibitor that works by:

• Irreversibly binding to the mutated KRAS G12C protein
• Locking it in an inactive state
• Inhibiting downstream signaling pathways responsible for tumor growth
• Reducing cancer cell proliferation and survival

This targeted mechanism offers precision treatment for patients with KRAS-driven tumors.

📌 Indications:

Sotoxen® 320 mg is indicated for:

• Locally advanced or metastatic non-small cell lung cancer (NSCLC)
• Patients with confirmed KRAS G12C mutation
• Disease progression after prior systemic therapy

💉 Dosage & Administration:

• Recommended dose: 960 mg once daily (typically 3 tablets of 320 mg)
• Taken orally with or without food
• Swallow tablets whole; do not crush or chew
• Continue treatment until disease progression or unacceptable toxicity

⚠️ Must be used under oncologist supervision.

⚠️ Precautions & Warnings:

• Monitor liver function tests (ALT, AST) regularly
• Risk of hepatotoxicity
• Monitor for interstitial lung disease (ILD)/pneumonitis
• Avoid use with strong CYP3A inducers/inhibitors
• Caution in patients with pre-existing lung disease

❌ Contraindications:

• Hypersensitivity to Sotorasib or any formulation component

🤰 Pregnancy & Lactation:

• Not recommended during pregnancy
• Breastfeeding should be avoided during treatment
• Use effective contraception during therapy

⚕️ Side Effects:

Common side effects include:

• Diarrhea
• Nausea
• Fatigue
• Elevated liver enzymes
• Musculoskeletal pain

Serious but less common:

• Hepatotoxicity
• Interstitial lung disease/pneumonitis

🧊 Storage Conditions:

• Store below 30°C
• Keep in a cool, dry place
• Protect from light and moisture
• Keep out of reach of children